New York-based pharmaceutical giant Pfizer (NYSE: PFE) has published a post hoc analysis of data from a Phase III study of Vyndaqel (tafamidis).
The analysis will bolster potential for a renewed bid for regulatory approval in the USA.
The research shows that treatment with Vyndaqel delays disease progression in patients with early-stage transthyretin familial amyloid polyneuropathy (TTR-FAP), a rare and fatal genetic disorder.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze